Effects of Arginine Vasopressin (AVP) Infusions on Circulating Concentrations of Platelet AVP, Factor VIII: C and von Willebrand Factor

Summary

To study the possible role of arginine vasopressin (AVP) in the control of haemostasis AVP infusions at 3 doses (0.1, 0.2 and 0.3 mU/kg/min) were performed in 6 male volunteers. Both plasma and platelet AVP concentrations rose in a dose-related manner. At doses of 0.2 and 0.3 mU/kg/min there was an increase in the plasma concentrations of both plasma Factor VIII and von Willebrand factor. The data support the hypothesis that AVP, by interacting with platelets and stimulating factor VIII and von Willebrand factor release, plays a role in the control of haemostasis.

Key words

Arginine vasopressin - Platelets - Factor VIII - von Wille-brand factor

• References

• 1 Peake IR. The nature of factor VIII. Clin Sci 1984; 67: 561-567
• 2 Bloom AL. Physiology of factor VIII. In Recent Advances in Blood Coagulation, 2nd edition Poller L. (Ed.). Vol 2 141-181 Churchill-Livingstone; Edinburgh: 1977
• 3 Mannucci PM, Aberg M, Nilsson IM, Robertson B. Mechanism of plasminogen activator and factor VIII increase after vasoactive drugs. Br J Haematol 1975; 30: 81-93
• 4 Prowse CV, Sas G, Gader A MA, Cort JH, Cash JD. Specificity in the factor VIII response to vasopressin infusion in man. Br J Haematol 1979; 41: 437-447
• 5 Mannucci PM, Canciani MT, Rota L, Donovan BS. Response of factor VII/von Willebrand factor to DDAVP in healthy subjects and patients with haemophilia A and von Willebrand’s disease. Br J Haematol 1981; 47: 283-293
• 6 Mannucci PM, Ruggeri ZM, Pareti FI, Capitano A. DDAVP, a new pharmacological approach to the management of haemophilia and von Willebrand’s disease. Lancet 1977; i: 869-872
• 7 Cash JD, Gader A MA, daCosta J. The release of plasminogen activator and Factor VIII to lysine vasopressin, arginine vasopressin, 1-Desamino-8-d-Arginine vasopressin, angiotensin and oxytocin in man. Brit J Haematol 1974; 27: 363-364
• 8 Barnhart MI, Chen S, Lusher JM. DDAVP: Does the drug have a direct effect on the vessel wall?. Thromb Res 1983; 31: 239-253
• 9 Booyse FM, Osikowicz G, Feder S. Effects of various agents on ristocetin-Willebrand factor activity in long-term cultures of von Willebrand and normal human umbilical vein endothelial cells. Thromb Haemostas 1981; 46: 668
• 10 Kitaguchi H, Hirata M, Funahara Y, Tada K, Okamoto S. Effect of vasoactive agents on factor VIII release from perfused isolated dog leg. Thromb Res 1979; 16: 159-173
• 11 Moffat EH, Giddings JC, Bloom AL. The effect of desamino-D-arginine vasopressin (DDAVP) and naloxone infusions on factor VIII and possible endothelial cell (EC) related activities. Br J Haematol 1984; 57: 651-662
• 12 Jard S. Vasopressin Receptors. Frontiers in Hormone Research 1985; 13: 89-104
• 13 Pliska V. Pharmacology of Deamino-D-Arginine Vasopressin. Frontiers in Hormone Research 1985; 13: 278-291
• 14 Haslam RJ, Rosson GM. Aggregation of human blood platelets by AVP. Am J Physiol 1972; 223: 958-967
• 15 Grant JA, Scrutton MC. Positive interaction between agonists in the aggregation response of human blood platelets: Interaction between ADP, adrenaline and AVP. Br J Haematol 1980; 44: 109-125
• 16 Preibisz JJ, Sealey JE, Laragh JH, Cody RJ, Weksler BB. Plasma and platelet AVP in essential hypertension and congestive heart failure. Hypertension 1983; 5: 1129-1138
• 17 Nussey SS, Bevan DH, Ang V TY, Jenkins JS. Arginine vasopressin in the human platelet. Abstract P79. Xth Congress of the International Society on Thrombosis and Haemostasis 1985
• 18 Jenkins JS, Ang V TY, Hawthorn J, Rossor MN, Iversen LL. Vasopressin, oxytocin and neurophysins in the human brain and spinal cord. Brain Res 1984; 291: 111-117
• 19 Laurell CB. Antigen-antibody crossed electrophoresis. Anal Biochem 1965; 10: 358-361
• 20 Giddings JC. Hereditary coagulation disorders: laboratory techniques. In Blood Coagulation and Haemostasis: A Practical Guide 1980 Thomsonn JM. (ed) 117-157 Churchill Livingstone; London: 1980
• 21 Evans RJ, Austen D EG. Assay of ristocetin co-factor using fixed platelets and a platelet counting technique. Br J Haematol 1977; 37: 289-294
• 22 Wade CE. Response regulation and actions of vasopressin during exercise: a review. Med Sci Sports Exerc 1984; 16: 506-511
• 23 Bichet D, Statalowicz V, Chaimovitz C, Schrier RW. Role of vasopressin in abnormal water excretion in cirrhotic patients. Ann Intern Med 1982; 96: 413-417
• 24 Baylis PH, Robertson GL. Arginine vasopressin response to insulin-induced hypoglycaemia in man. J Clin Endocrinol Metab 1981; 53: 935-940
• 25 Husain MK, Frantz AG, Chiarochi FF, Robinson AG. Nicotine stimulated release of neurophysin and AVP in humans. J Clin Endocrinol Metab 1975; 41: 1113-1117
• 26 Bonjour JP, Malvin RL. Plasma concentrations of ADH in conscious and anaesthetised dogs. Am J Physiol 1970; 218: 1128-1132
• 27 Belch J JF, McArdle BM, Burns P, Lowe G DO, Forbes CD. The effect of smoking on platelet behavior, fibrinolysis and haemorheo-logy in habitual smokers. Thromb Haemostas 1984; 51: 6-8
• 28 Baylis PH. Posterior pituitary function in health and disease. Clin Endocrinol Metab 1983; 12: 747-770
• 29 Fahrenholz F, Boer R, Crause P, Fritzsch G, Grzonka Z. Interactions of vasopressin agonists and antagonists with membrane receptors. Eur J Pharmacol 1984; 100: 47-58
• 30 Mannucci PM, Aberg M, Nilsson JM, Robertson B. Mechanism of plasminogen activator and Factor VIII increase after vasoactive drugs. Brit J Haematol 1975; 30: 81-93
• 31 Prowse CV, Sas G, Gader A MA, Cort JH, Cash JD. Specificity in the Factor VIII response to vasopressin infusion in man. Brit J Haematol 1979; 41: 437-447
• 32 Meucci P, Peake IR, Bloom AL. Factor VUI-related activities in normal, haemophilic and von Willebrand’s disease platelet fractions. Thromb Haemostas 1978; 40: 288-302
• 33 Rail LB, Bell GI, Caput D, Truett MA, Masiarz FR, Najarian RC, Valenzuella P, Anderson HD, Din N, Hansen B. Factor VIII :C synthesis in the kidney. Lancet i: 44 1985;